AzTrials
AzTrials

Sleep Apnea, ObstructiveEarly Phase 1NCT02261857

3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea

A Early Phase 1 study testing Personalized continuous positive airway pressure (CPAP) mask in people with Sleep Apnea, Obstructive and Craniofacial Abnormalities, run by Glenn Green at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether patient-specific computer-aided design (CAD) and three-dimensional (3D) printing can be utilized to produce personalized, effective continuous positive airway pressure (CPAP) masks for children with severe obstructive sleep apnea (OSA) and craniofacial anomalies who… Read more about this study

Who is it for?
Ages 1 year to 18 years
What is being tested?
Personalized continuous positive airway pressure (CPAP) mask
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteUnited States
Study dates
Sep 2013to Sep 2017
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • On-going need for CPAP therapy based on polysomnography
  • Inability to tolerate CPAP attributed to poor fit by a sleep clinician
  • The opinion of a sleep clinician that reasonable commercially available mask options have been exhausted
  • Caregivers must also be proficient in English to complete standard questionnaires.

Who cannot join

  • Subjects no longer needing CPAP therapy
  • Subjects able to successfully use a commercially available mask.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Michigan

    Ann Arbor, Michigan, 48109

Other trials in United States

About this study

Official title: Personalized Three-Dimensionally Printed CPAP Masks for Obstructive Sleep Apnea Therapy in Children With Craniofacial Anomalies

The purpose of this study is to determine whether patient-specific computer-aided design (CAD) and three-dimensional (3D) printing can be utilized to produce personalized, effective continuous positive airway pressure (CPAP) masks for children with severe obstructive sleep apnea (OSA) and craniofacial anomalies who encounter significant difficulty using CPAP because of poorly fitting masks despite exhausting available commercial mask options.

Read the detailed description

Obstructive sleep apnea (OSA) is a common problem in the general pediatric population, generally cited as between 1-5%, with morbidity ranging from daytime behavioral problems and inattention to cardiopulmonary effects including hypertension and ventricular hypertrophy. OSA is dramatically more prevalent among children with certain craniofacial anomalies and syndromes (e.g. Pierre-Robin, Treacher Collins, etc.), generally because of small, short jaws, midface hypoplasia, and/or disproportionally large tongues . While tonsillectomy and adenoidectomy is considered first line therapy for OSA in the general pediatric population, children with OSA due to craniofacial anomalies frequently require more aggressive intervention to improve their breathing at night, which often includes continuous positive airway pressure ventilation (CPAP). Most children who require CPAP therapy are able to find a mask that will adequately seal while providing acceptable comfort, however a small percentage of children encounter significant difficulty finding a functional CPAP interface, most often because of dysmorphic facial features. This can prove a significant barrier to effective CPAP therapy and lead to frustration on the part of patients' caregivers and providers, as well as the associated morbidity of untreated severe OSA. The purpose of this feasibility study is to investigate the use of patient-specific computational design and three-dimensional (3D) printing to produce personalized CPAP masks for children intolerant of standard CPAP masks due to poor fit secondary to craniofacial anomalies who encounter significant difficulty using CPAP because of poorly fitting masks despite exhausting available commercial mask options.

Study Design

This will be a prospective case study examining the feasibility of using patient-specific CAD and 3D printing technology to produce personalized CPAP masks for children intolerant of commercially available masks due to poor fit. Patients will be recruited from the pediatric otolaryngology, pediatric oral maxillofacial surgery, and pediatric sleep clinics at the University of Michigan Medical Center, with a target cohort of five.

Only patients of study team members will be included in the study, and no recruitment will take place outside the clinics of participating study team members. We anticipate the study period to last 3 years, though it may terminate sooner if recruitment targets are reached expeditiously.

After recruitment and consent of a potential study subject, each subject will undergo an initial mask-design evaluation with members of the research team. At this initial visit, the following will be performed:

  1. A head \& neck physical exam, which a focus on characteristics important for treatment of OSA (e.g. jaw size and position, tongue size and position, characteristics of palate, presence or absence of cleft, external nasal deformity, external or internal nasal valvular collapse)
  2. Review of patient's photographs
  3. Generation of a topographic model of the patient's facial anatomy utilizing the 3dMDface system (specifics below) which will be export as a Stereolithography (.STL) file.

The patient's facial .STL file will then be imported into a computer-aided design (CAD) modeling program (MimicsTM or MagicsTM, Materialise, Belgium). Contact points along the topographic model are drawn out and utilized for modeling of the custom mask. The custom mask model is then exported in .STL format for import into the 3D printer for fabrication using a fused-deposition modeling (FDM) method (Object Pro, Stratasys, Israel).

Once the mask has been fabricated, patients will undergo a mask-fit evaluation. If a mask appears to fit well, the patient will use it at home with home CPAP for one month of consistent use. They will then return for debriefing and re-evaluation, with subsequent iterations of mask design as needed. If the mask functions for the patient better than any other alternatives, the patient will be allowed to continue to use the mask for up to one year, with ongoing surveillance by the research team, assessing for mask durability and ongoing usage/compliance.

Data collection will include:

  • Objective data regarding the nature of each patient's obstructive sleep apnea and CPAP pressure requirements sleep-disordered breathing from the most recent available polysomnograms (sleep study, abbreviated PSG)
  • Information regarding all prior CPAP masks attempted
  • One month compliance data downloads from CPAP machines - with both the prior "best alternative" if usable, and with the customized mask, including percentage of days used, average hours usage, residual apnea-hypopnea index (AHI) and time spent in large leak per night.
  • Standardized interview with patients and their parents regarding other masks used and experience with the customized mask(s).
  • Descriptive anatomic information regarding facial anomalies contributing to poor mask fit, obtained from physical exam, photographs, and imaging studies.
  • Validated quality of life measures taken before and at completion of trial period with customized CPAP mask, including the Pediatric Sleep Questionnaire (PSQ) and the OSA-18 , to assess the impact of successful CPAP use for our patients.

Analysis will involve basic descriptive statistics to describe both the objective outcomes (e.g. compliance data from CPAP machines) and quality of life measures (PSQ and OSA-18 surveys) as well as information on individual experiences collected during interviews.

Additional Data on 3D Photography System

Patient facial modeling information will be obtained utilizing a 3dMDface system (3dMD, Atlanta, GA). The 3dMD system is a three-dimensional photography system which generates a three-dimensional model of the patient's face utilizing multiple convergent cameras (see Figure 1 below). The three-dimensional model is generated utilizing hybrid stereophotogrammetry, with software algorithms using both projected random patterns and texture of the skin (pores, freckles, etc.) to stereo-triangulate and generate a 3D surface image. The 3D model of the patient's face is created within the 3dMDvultus software system, which can then export the model in .STL format. No patient identifying information is stored within the .STL file.

All 3D photography sessions with study subjects will be performed or supervised by one of the members of the study team. There will be no cost associated with using the 3dMDface system. Utilizing 3D photography allows us to obtain the most time-accurate topographic information of the patient's face while avoiding the cost and risk associated with conventional CT or MRI imaging.

Data Included in Registry:

  • Pre- and post- intervention OSA-18 and PSQ questionnaire aggregates. Data to be recorded includes: sum score and mean score for each questionnaire.
  • Pre-intervention AHI and oxygen saturation (SpO2) nadir based on most recent sleep PSG.
  • Pre-intervention CPAP requirements based on most recent CPAP titration PSG.
  • Pre-intervention compliance data downloads from subject's CPAP machines from prior 1 month's use. Data to be recorded includes: percentage of days used, average hours usage, residual apnea-hypopnea index (AHI), size of leak in liters per minute, and time spent in large leak per night.
  • Post-intervention compliance data downloads from subject's CPAP machines from prior 1 month's use. Data to be recorded includes: percentage of days used, average hours usage, residual apnea-hypopnea index (AHI), size of leak in liters per minute, and time spent in large leak per night.

Data Registry QA:

  • Physical and electronic PDF versions of each data registry primary source (questionnaires, polysomnograms, and CPAP compliance reports) will be kept for the 5 years past the duration of the study. Data uploaded to the patient registry will be verified with the institutional IRB.
Being tested
Personalized continuous positive airway pressure (CPAP) mask
Keywords
Obstructive Sleep Apnea, Craniofacial Abnormalities, Pediatrics, Computer-Aided Design, Continuous Positive Airway Pressure, Three-Dimensional Printing, Additive Manufacturing
Medical subject headings
Sleep Apnea, Obstructive, Craniofacial Abnormalities

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Personalized continuous positive airway pressure (CPAP) maskDevice

    Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing

Study groups in NCT02261857
Study groupRoleWhat they receive
Intervention ArmExperimentalIntervention: Subjects will undergo assessment and a personalized CPAP mask device will be manufactured using patient-specific computer-aided design and 3D printing. The subject will use the personalized CPAP mask for 1 month of consistent use and post-intervention data will be collected for compare to historical control (see other arm)
Receives: Device: Personalized continuous positive airway pressure (CPAP) mask
Historical Control ArmNo interventionPre-interventional baseline data on subject OSA, CPAP compliance, and quality of life (QoL) measures will be collected to serve as historical controls.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in CPAP Compliance at 1 month

    Subject CPAP usage data will be downloaded from their CPAP machine before beginning the use to personalized mask (baseline) and after 1 month of consistent use of the personalized mask (1 month post-intervention). Average hours usage will be recorded and compared between baseline CPAP usage data and 1 month post-intervention CPAP usage data to assess efficacy of the personalized mask compared to the best prior alternative. Outcome will be measured as a numerical value in hours per night.

    Measured: 1 month

  2. Change in CPAP Leak Rate at 1 month

    Subject CPAP usage data will be downloaded from their CPAP machine before beginning the use to personalized mask (baseline) and after 1 month of consistent use of the personalized mask (1 month post-intervention). Leak in liters per minute will be recorded and compared between baseline CPAP usage data and 1 month post-intervention CPAP usage data to assess efficacy of the personalized mask compared to the best prior alternative. Outcome will be measured as a numerical value in liters per minute.

    Measured: 1 month

  3. Change in residual AHI on CPAP at 1 month

    Subject CPAP usage data will be downloaded from their CPAP machine before beginning the use to personalized mask (baseline) and after 1 month of consistent use of the personalized mask (1 month post-intervention). Residual apnea-hypopnea index (AHI) will be recorded and compared between baseline CPAP usage data and 1 month post-intervention CPAP usage data to assess efficacy of the personalized mask compared to the best prior alternative. Outcome will be measured as a numerical value denoting AHI.

    Measured: 1 month

  4. Change in time spent in large leak on CPAP at 1 month

    Subject CPAP usage data will be downloaded from their CPAP machine before beginning the use to personalized mask (baseline) and after 1 month of consistent use of the personalized mask (1 month post-intervention). Percentage (%) time spent in large leak per night will be recorded and compared between baseline CPAP usage data and 1 month post-intervention CPAP usage data to assess efficacy of the personalized mask compared to the best prior alternative. Outcome will be measured as a numerical percentage as a percentage of total time spent in large leak per night over total time using CPAP per night.

    Measured: 1 month

Secondary outcomes (8)
  1. Change in Quality of Life via OSA-18 questionnaire

    Subject's parents or legal guardians will complete OSA-18 questionnaire (validated OSA quality of of life questionnaires) pre-intervention (baseline) and at 1-month post-intervention. These will be compared to assess effect on quality of life of the interventional device. Outcome will be measured as a numerical value as sum of all question value responses.

    Measured: 1 month

  2. Safety outcomes: Comfort at baseline

    Subjects will be assessed clinically when first wearing the interventional device to ensure there are no issues with device fit, comfort, or undue forces on the face. Outcome will be measured as a binary numerical value with 0 denoting no issues with comfort and 1 denoting issues with comfort.

    Measured: Baseline

  3. Safety outcomes: Comfort at 1 month

    Subjects will be assessed clinically after using the personalized mask consistently for 1 month at home to ensure there are no issues with device fit, comfort or undue forces on the face. Subject's parents or legal guardians are instructed to contact the study team for earlier follow-up at anytime if any concerns about device fit or use occur. Outcome will be measured as a binary numerical value with 0 denoting no issues with comfort and 1 denoting issues with comfort.

    Measured: 1 month

  4. Safety outcomes: Skin reaction at 1 month

    Subjects will be assessed clinically after using the personalized mask consistently for 1 month at home to ensure there are no issues with skin reaction or breakdown on the face. Subject's parents or legal guardians are instructed to contact the study team for earlier follow-up at anytime if any concerns about device fit or use occur. Outcome will be measured as a binary numerical value with 0 denoting no issues with skin reaction and 1 denoting issues with skin reaction.

    Measured: 1 month

  5. Change in Quality of Life via PSQ questionnaire

    Subject's parents or legal guardians will complete PSQ questionnaire (validated OSA quality of of life questionnaires) pre-intervention (baseline) and at 1-month post-intervention. These will be compared to assess effect on quality of life of the interventional device. Outcome will be measured as a numerical value as sum of all question value responses.

    Measured: 1 month

  6. Safety outcomes: durability at 1 month

    Subjects will be assessed clinically after using the personalized mask consistently for 1 month at home to ensure there are no issues with excessive wear or tear of the personalized mask. Subject's parents or legal guardians are instructed to contact the study team for earlier follow-up at anytime if any concerns about device fit or use occur. Outcome will be measured as a binary numerical value with 0 denoting no issues with durability and 1 denoting issues with durability.

    Measured: 1 month

  7. Safety outcomes: Skin reaction at 12 months

    Subjects will be assessed clinically after using the personalized mask consistently for 12 months at home to ensure there are no issues with skin reaction or breakdown on the face. Subject's parents or legal guardians are instructed to contact the study team for earlier follow-up at anytime if any concerns about device fit or use occur. Outcome will be measured as a binary numerical value with 0 denoting no issues with skin reaction and 1 denoting issues with skin reaction.

    Measured: 12 months

  8. Safety outcomes: Durability at 12 months

    Subjects will be assessed clinically after using the personalized mask consistently for 12 months at home to ensure there are no issues with excessive wear or tear of the personalized mask. Subject's parents or legal guardians are instructed to contact the study team for earlier follow-up at anytime if any concerns about device fit or use occur. Outcome will be measured as a binary numerical value with 0 denoting no issues with durability and 1 denoting issues with durability.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2014 (estimated)
  2. Study startSep 2013
  3. Primary completionSep 2017
  4. Study completionSep 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02261857
Sponsor's protocol ID
HUM00078727
Status last verified
Apr 2020
First submitted
29 Sep 2014
Last updated
16 Apr 2020
Results posted
No
Data monitoring committee
No

Publications

  • Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, Schechter MS, Ward SD, Sheldon SH, Shiffman RN, Lehmann C, Spruyt K; American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012 Sep;130(3):e714-55. doi: 10.1542/peds.2012-1672. Epub 2012 Aug 27.

    PubMed 22926176
  • Brunetti L, Rana S, Lospalluti ML, Pietrafesa A, Francavilla R, Fanelli M, Armenio L. Prevalence of obstructive sleep apnea syndrome in a cohort of 1,207 children of southern Italy. Chest. 2001 Dec;120(6):1930-5. doi: 10.1378/chest.120.6.1930.

    PubMed 11742924
  • Amin RS, Kimball TR, Bean JA, Jeffries JL, Willging JP, Cotton RT, Witt SA, Glascock BJ, Daniels SR. Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Am J Respir Crit Care Med. 2002 May 15;165(10):1395-9. doi: 10.1164/rccm.2105118.

    PubMed 12016102
  • Duman D, Naiboglu B, Esen HS, Toros SZ, Demirtunc R. Impaired right ventricular function in adenotonsillar hypertrophy. Int J Cardiovasc Imaging. 2008 Mar;24(3):261-7. doi: 10.1007/s10554-007-9265-1. Epub 2007 Sep 6.

    PubMed 17846918
  • Leung LC, Ng DK, Lau MW, Chan CH, Kwok KL, Chow PY, Cheung JM. Twenty-four-hour ambulatory BP in snoring children with obstructive sleep apnea syndrome. Chest. 2006 Oct;130(4):1009-17. doi: 10.1378/chest.130.4.1009.

    PubMed 17035432
  • Luna-Paredes C, Anton-Pacheco JL, Garcia Hernandez G, Martinez Gimeno A, Romance Garcia AI, Garcia Recuero II. Screening for symptoms of obstructive sleep apnea in children with severe craniofacial anomalies: assessment in a multidisciplinary unit. Int J Pediatr Otorhinolaryngol. 2012 Dec;76(12):1767-70. doi: 10.1016/j.ijporl.2012.08.020. Epub 2012 Sep 11.

    PubMed 22980525
  • Plomp RG, Bredero-Boelhouwer HH, Joosten KF, Wolvius EB, Hoeve HL, Poublon RM, Mathijssen IM. Obstructive sleep apnoea in Treacher Collins syndrome: prevalence, severity and cause. Int J Oral Maxillofac Surg. 2012 Jun;41(6):696-701. doi: 10.1016/j.ijom.2012.01.018. Epub 2012 Apr 20.

    PubMed 22521672
  • Zandieh SO, Padwa BL, Katz ES. Adenotonsillectomy for obstructive sleep apnea in children with syndromic craniosynostosis. Plast Reconstr Surg. 2013 Apr;131(4):847-852. doi: 10.1097/PRS.0b013e3182818f3a.

    PubMed 23542256
  • Chervin RD, Hedger K, Dillon JE, Pituch KJ. Pediatric sleep questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Med. 2000 Feb 1;1(1):21-32. doi: 10.1016/s1389-9457(99)00009-x.

    PubMed 10733617
  • Franco RA Jr, Rosenfeld RM, Rao M. First place--resident clinical science award 1999. Quality of life for children with obstructive sleep apnea. Otolaryngol Head Neck Surg. 2000 Jul;123(1 Pt 1):9-16. doi: 10.1067/mhn.2000.105254.

    PubMed 10889473

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Personalized continuous positive airway pressure (CPAP) mask in people with Sleep Apnea, Obstructive and Craniofacial Abnormalities, run by Glenn Green at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in CPAP Compliance at 1 month (time frame: 1 month). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02261857, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in